A pilot study of lis-dexamfetamine dimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine-dependent adults with ADHD.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Who Took Part

The age groups tagged for this paper are adults, both men and women.

Thirty-two regular adult smokers with ADHD were randomized to receive LDX (n = 17) or placebo (n = 15) in addition to nicotine patch concurrent with a quit attempt.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and pilot study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.

It is described as a pilot, a small early test of whether a larger Therapeutic nicotine (patch, non-peptide) study would be practical.

What Was Measured

The subject headings attached to it are Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Dextroamphetamine, Lisdexamfetamine Dimesylate, Pilot Projects, Smoking and Smoking Cessation.

Author keywords: adult ADHD and lis-dexamfetamine dimesylate.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Journal of attention disorders), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.